EU/3/13/1225

About

On 16 January 2014, orphan designation (EU/3/13/1225) was granted by the European Commission to Eiger Biopharmaceuticals Europe Limited, United Kingdom, for lonafarnib for the treatment of hepatitis delta virus infection.

Key facts

Active substance
Lonafarnib
Disease / condition
Treatment of hepatitis delta virus infection
Date of decision
16/01/2014
Outcome
Positive
Orphan decision number
EU/3/13/1225

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Eiger Biopharmaceuticals Europe Limited
30 Upper High Street
Thame
Oxon OX9 3EZ
United Kingdom
Tel. +44 (0)18442 61155
E-mail: info@eigerbio.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating